Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir) and ribavirin cures hepatitis C virus (HCV) at mostly high rates among those with decompensated cirrhosis or who have had recurrent hep C after a liver transplant, MedPage Today reports. Researchers in the SOLAR-2 trial gave 12 or 24 weeks of the regimen to 328 people with genotype 1 or genotype 4 of the virus, more than 75 percent of whom were treatment experienced. They presented their findings at the 50th International Liver Congress in Vienna, Austria.
Continue reading at: hepmag.com/articles/SOLAR_2...
